To whom it may concern:

Company Name: TOHO HOLDINGS CO., LTD.
Corporate Representative: Atsushi Udoh, President and Representative Director
(First Section of Tokyo Stock Exchange Securities Code:8129)
Contact: Makoto Kawamura, Director and General Manager, Corporate Management Division and Corporate Planning and Investor Relations Department (TEL: 81-3-6838-2803)

Announcement of Investment in Drawbridge Health, Inc.

TOHO HOLDINGS CO., LTD. (Headquarters: Tokyo; President and Representative Director: Atsushi Udoh; hereinafter, “TOHO HOLDINGS”) announces that it has invested in Drawbridge Health, Inc., a U.S. healthcare technology company (Headquarters: Menlo Park, California, U.S.; CEO & Board Director: Lee McCracken; hereinafter, “Drawbridge Health”), as described below.

1. Reason for investment

TOHO HOLDINGS is a corporate group active in medical, nursing and healthcare fields, engaged in pharmaceutical wholesaling, dispensing pharmacy, manufacturing and sales of pharmaceuticals, and development and provision of customer support systems under the corporate slogan "Total Commitment to Good Health". TOHO HOLDINGS also proactively promotes initiatives for regional medical collaboration, nursing and home care.

Drawbridge Health has developed the OneDraw™ Blood Collection Device, a blood sampling solution, which will enable simplified collection and transportation of dried blood samples, for clinical lab testing. The OneDraw Blood Collection Device, which is the enabling technology for the OneDraw A1C Test System, has received 510(k) clearance from the U.S. FDA and completed the European CE mark process. OneDraw is a small device that draws, collects, and stabilizes a capillary blood sample from the upper arm in a convenient and comfortable way. OneDraw has been designed so that once collected, a blood sample is stabilized in a removable cartridge and shipped to a designated certified clinical laboratory for testing. With the advantages of being a virtually pain-free and simplified method for remote blood collection anytime and anywhere, there are high expectations not only for adoption of the new technology in the fields of diabetes and lifestyle disease, but for advancing telemedicine. The adoption of OneDraw can also be expected to extend to enabling testing for biomarkers associated with overall wellness and various diseases.

TOHO HOLDINGS will fully collaborate to expand the blood collection technology from Drawbridge Health in the Japanese market as well as support their research and development efforts through this investment.

2. Overview of Drawbridge Health, Inc.

Founded in August 2015 by GE Ventures and GE Healthcare, Drawbridge Health is a healthcare technology company focused on reinventing the blood draw experience, enabling comfortable convenient blood sample collection anytime and anywhere. By integrating engineering, chemistries, and modular design, Drawbridge Health has developed a people-friendly system for collecting and stabilizing blood samples, opening new doors to enable access to important health information. For more information, please visit the website (www.drawbridgehealth.com).

3. Forward looking outlook

Impact to consolidated performance is minor.